Palliative uses of methylphenidate in patients with cancer: A review

被引:76
作者
Rozans, M
Dreisbach, A
Lertora, JJL
Kahn, MJ
机构
[1] Tulane Univ, Sch Med, Sect Hematol Med Oncol, Dept Med, New Orleans, LA 70131 USA
[2] Tulane Univ, Sch Med, Dept Pharmacol, New Orleans, LA 70131 USA
关键词
D O I
10.1200/JCO.20.1.335
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Cancer is, unfortunately, often a terminal disease. The goal of therapy for many patients with cancer is palliation of symptoms common at the end of life, including pain, depression, and cognitive dysfunction. Methylphenidate is a psychostimulant most commonly used in the treatment of attention deficit hyperactivity disorder. In this report, we review the use of methylphenidate in the palliative care of patients with cancer. Methods: This review was written on the basis of a computerized literature search of Medline. We considered all English language publications from 1966 to present using the following key words: methylphenidate, palliative care, and cancer. Forty-nine articles were identified as being relevant for this review. Results: On the basis of this review, we came to the conclusion that methylphenidate is used to ameliorate opioid-induced somnolence, to augment the analgesic effects of opioids, to treat depression, and to improve cognitive function in patients with cancer. Conclusion:. The medical literature supports the palliative use of methylphenidate in the care of patients with cancer. Further placebo-controlled trials are needed to elucidate the precise role that methylphenidate will have in providing symptom relief to dying patients. (C) 2001 by American Society of Clinical Oncology.
引用
收藏
页码:335 / 339
页数:5
相关论文
共 48 条
[1]   CANCER STATISTICS, 1991 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T .
CA-A CANCER JOURNAL FOR CLINICIANS, 1991, 41 (01) :19-36
[2]   THE USE OF METHYLPHENIDATE IN PATIENTS WITH INCIDENT CANCER PAIN RECEIVING REGULAR OPIATES - A PRELIMINARY-REPORT [J].
BRUERA, E ;
FAINSINGER, R ;
MACEACHERN, T ;
HANSON, J .
PAIN, 1992, 50 (01) :75-77
[3]  
BRUERA E, 1987, CANCER TREAT REP, V71, P67
[4]   NEUROPSYCHOLOGICAL EFFECTS OF METHYLPHENIDATE IN PATIENTS RECEIVING A CONTINUOUS INFUSION OF NARCOTICS FOR CANCER PAIN [J].
BRUERA, E ;
MILLER, MJ ;
MACMILLAN, K ;
KUEHN, N .
PAIN, 1992, 48 (02) :163-166
[5]   DEPRESSION IN HOSPITALIZED CANCER-PATIENTS [J].
BUKBERG, J ;
PENMAN, D ;
HOLLAND, JC .
PSYCHOSOMATIC MEDICINE, 1984, 46 (03) :199-212
[6]   CHARACTERIZATION OF METHYLPHENIDATE AND NOMIFENSINE INDUCED DOPAMINE RELEASE IN RAT STRIATUM USING INVIVO BRAIN MICRODIALYSIS [J].
BUTCHER, SP ;
LIPTROT, J ;
ABURTHNOTT, GW .
NEUROSCIENCE LETTERS, 1991, 122 (02) :245-248
[7]  
Challman TD, 2000, MAYO CLIN PROC, V75, P711
[8]  
CHIARELLO RJ, 1987, ARCH GEN PSYCHIAT, V44, P286
[9]  
COOK EH, 1995, AM J HUM GENET, V56, P993
[10]   Psychostimulant drugs potentiate morphine analgesia in the formalin test [J].
Dalal, S ;
Melzack, R .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1998, 16 (04) :230-239